Equities Analysts Offer Predictions for Affimed Q1 Earnings

Affimed (NASDAQ:AFMD) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Affimed in a research note issued on Tuesday, December 17th. Leerink Partnrs analyst D. Graybosch forecasts that the biopharmaceutical company will earn ($0.59) per share for the quarter. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share.

Other analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Stifel Nicolaus lowered their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Wells Fargo & Company dropped their target price on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Affimed in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Stock Up 0.8 %

AFMD stock opened at $1.19 on Friday. Affimed has a 1-year low of $1.14 and a 1-year high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $2.92 and its 200-day moving average is $4.06.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in Affimed in the 3rd quarter valued at about $44,000. Choreo LLC acquired a new stake in shares of Affimed in the second quarter valued at approximately $54,000. FMR LLC raised its position in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the last quarter. Intellectus Partners LLC lifted its holdings in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the last quarter. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.